tbuckley/cabot-search huggingface dataset:
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
Authors: Wan Ling Tan, Kevin L.M. Chua, Chia-Chi Lin, Victor H.F. Lee, Lye Mun Tho, Anthony W. Chan, Gwo Fuang Ho, Thanyanan Reungwetwattana, James C. Yang, Dong-Wan Kim, Ross A. Soo, Yong Chan Ahn, Hiroshi Onishi, Myung-Ju Ahn, Tony S.K. Mok, Daniel S.W. Tan, Fan Yang
Journal: Journal of Thoracic Oncology (2019)

Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a clinical challenge. Recent changes in the American Joint Commission on Cancer staging to the eighth edition has led to a shift in TNM stage grouping and redefined the subcategories (IIIA–C) in stage III NSCLC for better prognostication. Although concurrent chemoradiotherapy has remained standard-of-care for stage III NSCLC for almost 2 decades, contemporary considerations include the impact of different molecular subsets of NSCLC, and the roles of tyrosine kinase inhibitors post-definitive therapy and of immune checkpoint inhibitors following chemoradiotherapy. With rapid evolution of diagnostic algorithms and expanding treatment options, the need for interdisciplinary input involving multiple specialists (medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists and thoracic surgeons) has become increasingly important. The unique demographics of Asian NSCLC pose further challenges when applying clinical trial data into clinical practice. This includes differences in smoking rates, prevalence of oncogenic driver mutations, and access to health care resources including molecular testing, prompting the need for critical review of existing data and identification of current gaps. In this expert consensus statement by the Asian Thoracic Oncology Research Group, an interdisciplinary group of experts representing Hong Kong, Korea, Japan, Taiwan, Singapore, Thailand, Malaysia, and Mainland China was convened. Standard clinical practices for stage III NSCLC across different Asian countries were discussed from initial diagnosis and staging through to multi-modality approaches including surgery, chemotherapy, radiation, targeted therapies, and immunotherapy.
Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies
Authors: Margaux Damge, Sabine Furst, Bénédicte Devictor, Samia Harbi, Joseph Ciccolini, Angela Granata, Thomas Pagliardini, Boris Calmels, Claude Lemarie, Luca Castagna, Valerio Maisano, Faezeh Legrand, Anne-Marie Stoppa, Reda Bouabdallah, Evelyne D'Incan, Norbert Vey, Christian Chabannon, Didier Blaise, Raynier Devillier
Journal: Blood (2019)
A Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim (Dulastin®) after Single Administration in Pediatric Patients
Authors: Kyung Taek Hong, Soyoung Lee, Jaeseong Oh, Jung Yoon Choi, Hee Young Shin, Kyung-Sang Yu, Hyoung Jin Kang
Journal: Blood (2019)
Harnessing a Novel Dyrk1a-Ablim2-MKL1 Regulatory Module in Megakaryocyte Morphogenesis to Enable Scalable Platelet "Pharming"
Authors: Kamaleldin Elagib, Ashton Brock, Goar Mosoyan, Cara Clementelli, Lorrie Delehanty, Alexandra Pacheco-Benichou, Corinne Fruit, Thierry Besson, Stephen Morris, Koji Eto, Camelia Iancu-Rubin, Adam Goldfarb
Journal: Blood (2019)
Pneumocystis carinii Pneumonia
Authors: J. COLLAZOS
Journal: Annals of Internal Medicine (1985)

Letters and Corrections1 January 1985Pneumocystis carinii PneumoniaJ. COLLAZOS, M.D., C. BENEITEZ, M.D., C. PEREZ-BARBA, M.D., J. MERINO, M.D.J. COLLAZOS, M.D.Search for more papers by this author, C. BENEITEZ, M.D.Search for more papers by this author, C. PEREZ-BARBA, M.D.Search for more papers by this author, J. MERINO, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-1-137_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Kovacs and associates (1), in their comparative analysis ofPneumocystis cariniipneumonia in patients with the acquired immunodeficiency syndrome and other immunodeficiencies, report differences in the clinical behaviour of the pneumonia between the two groups of patients: those with the acquired immunodeficiency syndrome had a more insidious onset. We believe, however, that the clinical data they offer can be interpreted differently. Their Table 2 shows clinical data from both groups of patients. The main differential features are a lower mean respiratory rate, higher median oxygen tension (with room air) and a longer median duration of symptoms at...Reference1. KOVACSHIEMENZMACHER JJA. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663-71. LinkGoogle Scholar1. KOVACSHIEMENZMACHER JJA. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663-71. LinkGoogle Scholar2. . Acquired immunodeficiency syndrome (AIDS) update—United States. MMWR. 1983;32:309-11. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Hospital Provincial 03013 Alicante Spain PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPneumocystis jirovecii and PneumocystosisPneumocystis cariniiPulmonary manifestations of AIDS 1 January 1985Volume 102, Issue 1Page: 137-138KeywordsAIDSImmunodeficienciesImmunohistochemistryOxygenPneumocystis carinii pneumoniaPneumoniaRespiratory rate Issue Published: 1 January 1985 PDF DownloadLoading ...
Plant-Based Dietary Patterns and Incidence of Type 2 Diabetes
Authors: Clara Gómez-Donoso, Maira Bes-Rastrollo, Miguel A. Martínez-González
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration
Authors: Michael R. Savona, Hagop M. Kantarjian, Gail J. Roboz, Casey L. O'Connell, Katherine J. Walsh, Raoul Tibes, Karen W.L. Yee, Wendy Stock, Elizabeth A. Griffiths, Elias Jabbour, Scott D. Lunin, Todd L. Rosenblat, Nikolai A. Podoltsev, Jean-Pierre Issa, Xiang Yao Su, Mohammad Azab, Guillermo Garcia-Manero
Journal: Blood (2019)
P2.05 Real World Data on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Use in Advanced Non-small Cell Lung Cancer from a Latin American Cohort
Authors: M. Galvez-Nino, R. Ruiz, K. Roque, J. Moreno, N. Valdivieso, M. Olivera, Y. Miranda, G. Maquera, O. Cabero, M. Guillen, V. Rojas, E. Amorin, L. Mas
Journal: Journal of Thoracic Oncology (2019)
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Authors: Jonathon B. Cohen, Jeffrey M. Switchenko, Krithika Shanmugasundaram, Subir Goyal, Oscar Calzada, Michael C. Churnetski, Bhaskar Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J. Gordon, Alexey Danilov, Natalie S Grover, Stephanie Mathews, Madelyn Burkart, Reem Karmali, Yazeed Sawalha, Brian T. Hill, Nilanjan Ghosh, Steven I Park, Narendranath Epperla, David A. Bond, Talha Badar, Kristie A. Blum, Mehdi Hamadani, Timothy S. Fenske, Mary-Kate Malecek, Peter Martin, Jin Guo, Christopher R. Flowers, Brad S. Kahl
Journal: Blood (2019)
“Fake doctor” is charged with manslaughter after four patient deaths in Germany
Authors: Ned Stafford
Journal: BMJ (2019)

A 48 year old woman with no medical degree who worked as an assistant doctor at a hospital in Germany has been arrested on suspicion of manslaughter over the deaths of four patients, according to prosecutors in Kassel in central Germany.

The woman, using forged documents that stated that she was a medical doctor, was hired as an anaesthesiologist at the Hospital zum Heiligen Geist (Hospital of the Holy Spirit) in …
Phase I Study of Cord Blood Transplantation with Intra-Bone Marrow Injection of Mesenchymal Stem Cells
Authors: Tatsunori Goto, Makoto Murata, Tetsuya Nishida, Seitaro Terakura, Sonoko Kamoshita, Yuichi Ishikawa, Yoko Ushijima, Yoshiya Adachi, Katsuyoshi Kato, Akihiro Hirakawa, Satoshi Nishiwaki, Nobuhiro Nishio, Yoshiyuki Takahashi, Yoshihisa Kodera, Tadashi Matsushita, Hitoshi Kiyoi
Journal: Blood (2019)
Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience
Authors: Hamza Hashmi, Jeffrey Lancet, Asmita Mishra, Kendra L. Sweet, Rami S. Komrokji, Hugo F. Fernandez, Lia Perez, Farhad Khimani, Michael Nieder, Hany Elmariah, Joseph Pidala, Nelli Bejanyan, Alan F. List, Claudio Anasetti, Taiga Nishihori
Journal: Blood (2019)
Mebendazole Mediates Its Anti-Leukemic Effects By Proteasomal Degradation of GLI Transcription Factors Via Inhibition of HSP70/90-Chaperone Activity in Acute Myeloid Leukemia in a Preclinical and Clinical Setting
Authors: Fabian Freisleben, Hauke Stamm, Jana Muschhammer, Vanessa Thaden, Franziska Modemann, Alexander Krispien, Franziska Brauneck, Jasmin Wellbrock, Walter Fiedler
Journal: Blood (2019)
α-Particle–Emitter Radiopharmaceutical Therapy: Resistance Is Futile
Authors: George Sgouros
Journal: Cancer Research (2019)

Abstract Alpha-emitter radiopharmaceutical therapy (α-RPT) is a treatment modality that is impervious to conventional cellular resistance mechanisms because of the unique properties of the α-particle. Radiobiological studies of α-particle emitters have been few as they require detailed consideration of both biology and physics. Clinical studies of this radiation delivery modality have shown highly promising results in cancers that are resistant to other treatments. The work by Yard and colleagues published in this issue introduces an innovative approach to radiobiological investigations of α-RPT and highlights the specific physics considerations required to properly investigate this multidisciplinary treatment modality. See related article by Yard et al., p. 5640
Vector-borne transmission of Zika virus in Europe, southern France, August 2019
Authors: Sandra Giron, Florian Franke, Anne Decoppet, Bernard Cadiou, Thierry Travaglini, Laurence Thirion, Guillaume Durand, Charles Jeannin, Grégory L’Ambert, Gilda Grard, Harold Noël, Nelly Fournet, Michelle Auzet-Caillaud, Christine Zandotti, Samer Aboukaïs, Pascal Chaud, Saby Guedj, Lakri Hamouda, Xavier Naudot, Anne Ovize, Clément Lazarus, Henriette de Valk, Marie-Claire Paty, Isabelle Leparc-Goffart
Journal: Eurosurveillance (2019)

On 1 October 2019, a locally-acquired Zika virus disease case was laboratory confirmed in Hyères, Var department. Active case finding identified two additional locally-acquired cases living within 90 m, with symptom onset 8 days before the index case. Extensive patient interviews did not yield information supporting transmission through sexual contact or substances of human origin. Vector-borne transmission by local Aedes albopictus mosquitoes is the most likely mode of transmission. Here we describe the public health response.
CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
Authors: Mazyar Shadman, Ajay K. Gopal, Stephen D. Smith, Ryan C. Lynch, Chaitra S. Ujjani, Cameron J. Turtle, Adam Greenbaum, Mary Redman, Cecilia Yeung, Martina Sersch, Edus H. Warren, David G. Maloney, Brian G. Till
Journal: Blood (2019)
Comparison of the Copan WASPLab incorporating the BioRad expert system against the SIRscan 2000 automatic for routine antimicrobial disc diffusion susceptibility testing
Authors: A. Cherkaoui, G. Renzi, A. Fischer, N. Azam, D. Schorderet, N. Vuilleumier, J. Schrenzel
Journal: Clinical Microbiology and Infection (2019)
RTHP-37. RE-IRRADIATION OF GLIOMATOSIS CEREBRI WITH WHOLE BRAIN PULSED REDUCED DOSE RATE RE-IRRADIATION
Authors: Adam Burr, Colin Harari, H Ian Robins, Steven Howard
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Gliomatosis cerebri was removed from the 2016 WHO classification but the clinical problem of gliomatosis remains. For many of these patients, re-irradiation of the whole brain may be the only option. We have employed pulsed reduced dose rate (PRDR) radiation therapy to limit the toxicity of whole brain re-irradiation in this patient population. METHODS Consecutive patients were identified from an institutional database of patients treated with PRDR radiation to the whole brain between 2001 and 2016. Patients were treated by delivering a 20 cGy pulse of radiation every 3 minutes to opposed lateral fields with custom blocks using 6 MV photons, delivering radiation at an effective dose rate of 6.67 cGy/minute. RESULTS A total of sixteen patients were identified who underwent re-treated with WBRT. The median age was 45 (28–66) with a median KPS of 80 (range 60–100). 15 of 16 patients had high grade gliomas. The most common dose was 30 Gy in 15 fractions (range 24–41.4 Gy), giving a median total dose of 90.75 Gy (range 61.4–100.8 Gy). Median overall survival from re-irradiation was 3.8 months (range 0.1–17.0 months) and overall survival from first progression was 11.2 months. 25% of patients survived over 6 months following treatment and the overall response rate was 25% (3 PRs, 1 stable). No grade 4 or grade 5 toxicities were attributable to pulsed reduced dose rate radiation therapy. CONCLUSIONS PRDR radiation therapy provides a potential therapeutic intervention for progressive gliomatosis cerebri, providing a treatment option that can be implemented where no trial is available. As survival is short, these results will assist in counseling patients in considering re-irradiation versus supportive care.
Hypertrophic Osteoarthropathy in a Patient With Primary Hepatic Angiosarcoma
Authors: Jun Zhang, Mengjie Dong, Zhanxiong Yi, Congcong Yu
Journal: Clinical Nuclear Medicine (2019)

Abstract Primary hepatic angiosarcoma was diagnosed in a 59-year-old woman who presented an arthralgia of limbs and dry cough for 6 weeks. Physical examination revealed digital clubbing. A 99m Tc-MDP bone scintigraphy showed diffusely increased uptake along the cortical margins of long bones, suggesting hypertrophic osteoarthropathy.
TMOD-14. RADIOGRAPHIC, STIMULATED RAMAN HISTOLOGIC, AND MULTIPLEXED RNA-SEQUENCING ANALYSIS OF POST-TREATMENT RECURRENT HIGH-GRADE GLIOMAS
Authors: Akshay Save, Todd Hollon, Zia Farooq, Deborah Boyett, Andrea Hawkins-Daarud, Hyunsoo Yoon, Kyle Singleton, Kamala Clark-Swanson, Jing Li, Kristin Swanson, Christian Freudiger, Daniel Orringer, Andrew Lassman, Peter Sims, Jack Grinband, Peter Canoll, Jeffrey Bruce
Journal: Neuro-Oncology (2019)

Abstract High-grade gliomas (HGGs) nearly always recur after standard initial treatment, and the resulting mixture of recurrent tumor and treatment-induced reactive changes presents major diagnostic challenges. Anatomical imaging, such as MRI, cannot adequately distinguish progressive disease from treatment effect (pseudo-progression). Furthermore, there is marked intra-tumoral heterogeneity, such that some areas of a tumor may demonstrate necrotic treatment effect and others frank recurrence. Due to this difficulty reliably differentiating between these two clinical findings, analytic methods using multiple modalities are necessary to further our understanding of this disease process. To this end, we sought to correlate radiographic, histopathologic and molecular features of surgically sampled post-treatment suspected recurrence to identify markers distinguishing tumor growth from treatment effect. We performed Stimulated Raman Histology (SRH) imaging and highly multiplexed RNA-sequencing (PLATE-seq) on 84 MRI-localized biopsies from 39 patients with clinically suspected recurrent HGG. The SRH images were classified as recurrent tumor or gliotic/reactive tissue using a convolutional neural network trained on an independent cohort including a large set of recurrent HGG, and an automated cell-counting algorithm was used to quantify cellularity from the SRH image of each sample. Differential gene expression analysis of the PLATE-seq data was used to identify gene sets that distinguish recurrent tumor from treatment effect, and single sample gene set variation analysis (GSVA) was used to further assess the molecular and cellular composition of each MRI-localized sample. The histopathologic and molecular features of each sample were also correlated with the MRI features of the corresponding biopsy sites, and this data is currently being used to train machine learning models that predict the distribution of recurrent tumor and treatment-induced reactive changes within a patient’s radiographic lesion. These predictive radiomic models will help to guide neurosurgical sampling, and improve our ability to monitor glioma progression and response to therapy.
Role of the Child Psychiatrist
Authors: R. Moody
Journal: BMJ (1965)

BMICISH 477 estimated at similar intervals before and after feeding of the drug.The results of the first series of experiments can be seen in Table I and the second series of experiments in Table II.It can be seen that the normal serum S.G.O.T. values varied from 0.5 unit to 7.5 units.In no instance did the S.G.O.T. value suddenly rise after administering the steroid to any rabbit.In only one animal the S.G.O.T. level rose to 6.2 units from 0.5 unit after it suffered an injury to the right hind- leg which was possibly responsible for this rise.This rabbit had to be sacrificed.The results obtained with these two anovulatory steroids indicate that in rabbits they have shown to be devoid of any hepatotoxic effect when hepadc damage was evaluated by estimating the S.G.O.T. level in serum.This is the method which Eisalo et al.5 have mentioned as being the only one which would detect these changes.These authors state that this type of hepatic injury cannot be detected by tests like total bilirubin or alkaline phosphatase.
Diseases of the Cardiovascular System
Authors: Irvine H. Page, A. C. Corcoran
Journal: Annual Review of Medicine (1951)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around the globe, killing more than 4 million people and causing a severe economic crisis. ...Read More
STEM-21. INVESTIGATING DOT1L AS AN EPIGENETIC VULNERABILITY IN BRAIN TUMOR STEM CELLS
Authors: Danielle Bozek, Graham MacLeod, Xiaoguang Hao, Nishani Rajakulendran, Moloud Ahmadi, Peter Dirks, Stephane Angers, Artee Luchman, Sam Weiss
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM), the most common and aggressive primary adult brain cancer, is thought to be driven by a small subpopulation of brain tumor stem cells (BTSCs). BTSCs exhibit shared properties with normal stem cells such as self-renewal and multilineage differentiation. These stem cell properties have been proposed to underlie GBM tumorigenicity, treatment evasion and contribute to tumor heterogeneity. To investigate the biology underlying the stem cell properties of GBM, we compared gene essentiality profiles for a panel of BTSCs, fetal neural stem cells and non-GBM cell lines using a CRISPR Cas9 knockout library. Interestingly, from these screens, we identified the histone methyltransferase disrupter of telomeric silencing-1-like (DOT1L) as an essential gene for the growth of BTSCs and fetal neural stem cells but not for non-GBM cell lines. DOT1L is the only known histone methyltransferase responsible for histone 3 lysine 79 methylation, an epigenetic mark associated with active gene transcription. The role of this epigenetic regulator in BTSCs was investigated in depth using EPZ-5676, a clinically relevant small molecule inhibitor. Short-term treatment with EPZ-5676 in BTSCs showed minimal effects on cell viability but led to striking morphological changes, increased neuronal and astrocytic differentiation and a reduction in self-renewal. Longer treatment periods with EPZ-5676 led to a decrease in BTSC proliferation and an increase in apoptosis. Furthermore, BTSCs pretreated with EPZ-5676 led to slowed orthotopic tumor growth and improved overall survival in a SCID mouse model. Overall, these findings suggest DOT1L epigenetically regulates GBM stem cell properties and tumor growth. We are further investigating the mechanisms underlying DOT1L regulation of gene expression in BTSCs with the goal of improving the field’s understanding of epigenetics and the therapeutic implications of targeting epigenetic processes in GBM.
Pharmacokinetic Analysis of [18F]FAZA Dynamic PET Imaging Acquisitions for Highlighting Sacrum Tumor Profiles
Authors: Claire Provost, Hamid Mammar, Anne Belly-Poinsignon, Olivier Madar, Laurence Champion
Journal: Clinical Nuclear Medicine (2019)

Abstract A patient enrolled in a clinical trial (NCT02802969) with suspicion of chordoma underwent an [ 18 F]FAZA PET/CT, a radiolabeled nitroimidazole analog of hypoxia PET imaging. The patient's images showed a different tumor profile compared to those observed in other hypoxic or nonhypoxic chordoma patients. The motivation for using [ 18 F]FAZA pharmacokinetic imaging was to compare this profile with histologically confirmed cases of chordoma. Through visual imaging and quantification of blood and tumor time-activity curves, we excluded the hypothesis that it was a chordoma, diagnosing a paraganglioma.